{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.8","upperLimit":"72.1","value":"33.6"},{"groupId":"OG001","lowerLimit":"18.4","upperLimit":"32.0","value":"23.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"181"}],"units":"Participants"}],"description":"Overall Survival is defines as the time from registration to death due to any cause. It is estimated using the Kaplan-Meier method with confidence intervals presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"See detailed description or participant flow.","id":"OG000","title":"Phase I - Alemtuzumab and Combination Chemotherapy"},{"description":"See detailed description or participant flow.","id":"OG001","title":"Phase II - Alemtuzumab and Combination Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"All patients who registered, received protocol treatment, and were eligible were evaluated for this endpoint. Phase I patients were included with the phase II patients for this analysis.","reportingStatus":"POSTED","timeFrame":"9 years 4 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}